[Neurological side effects of checkpoint inhibitors].
Neurologische Nebenwirkungen von Checkpoint-Inhibitoren.
Encephalitis
Multiple sclerosis
Myopathies
Neuropathies
Tumors
Journal
Der Nervenarzt
ISSN: 1433-0407
Titre abrégé: Nervenarzt
Pays: Germany
ID NLM: 0400773
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
pubmed:
4
8
2018
medline:
13
9
2019
entrez:
4
8
2018
Statut:
ppublish
Résumé
In recent years the treatment of many tumor entities has been revolutionized by the use of modern immunotherapies with checkpoint inhibitors; however, good response rates are contrasted by many immune-mediated side effects. Neurological immune-mediated side effects are rare but often severe complications of checkpoint inhibitor treatment. A systematic search in the PubMed and Web of Sciences databases was carried out for case reports and studies on neurological side effects during checkpoint inhibitor treatment. A total of 42 articles on neurological side effects of checkpoint inhibitors with a total of 85 reported cases could be identified. The most frequently reported neurological side effects were myopathies, neuropathies, diseases of the neuromuscular endplates and encephalitides. Among those, encephalitides and myopathies with accompanying myocarditis were associated with the highest morbidity and mortality. Against the background of a rapidly increasing use of checkpoint inhibitors, this article provides an overview of currently available reports on the clinical courses of neurological side effects. Controlled studies on the treatment of neurological side effects are lacking. From case studies it can be assumed that early steroid treatment increases the probability of a complete remission of neurological symptoms. Typical symptom constellations must therefore be rapidly recognized and an immunosuppressive treatment must be initiated.
Sections du résumé
BACKGROUND
BACKGROUND
In recent years the treatment of many tumor entities has been revolutionized by the use of modern immunotherapies with checkpoint inhibitors; however, good response rates are contrasted by many immune-mediated side effects. Neurological immune-mediated side effects are rare but often severe complications of checkpoint inhibitor treatment.
METHOD
METHODS
A systematic search in the PubMed and Web of Sciences databases was carried out for case reports and studies on neurological side effects during checkpoint inhibitor treatment.
RESULTS
RESULTS
A total of 42 articles on neurological side effects of checkpoint inhibitors with a total of 85 reported cases could be identified. The most frequently reported neurological side effects were myopathies, neuropathies, diseases of the neuromuscular endplates and encephalitides. Among those, encephalitides and myopathies with accompanying myocarditis were associated with the highest morbidity and mortality.
CONCLUSION
CONCLUSIONS
Against the background of a rapidly increasing use of checkpoint inhibitors, this article provides an overview of currently available reports on the clinical courses of neurological side effects. Controlled studies on the treatment of neurological side effects are lacking. From case studies it can be assumed that early steroid treatment increases the probability of a complete remission of neurological symptoms. Typical symptom constellations must therefore be rapidly recognized and an immunosuppressive treatment must be initiated.
Identifiants
pubmed: 30073487
doi: 10.1007/s00115-018-0571-8
pii: 10.1007/s00115-018-0571-8
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Types de publication
Journal Article
Systematic Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
138-147Références
J Immunother. 2007 Nov-Dec;30(8):825-30
pubmed: 18049334
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
J Neurol. 2008 May;255(5):756-7
pubmed: 18283392
J Immunother. 2009 Feb-Mar;32(2):203-5
pubmed: 19238020
Ann Oncol. 2011 Apr;22(4):991-3
pubmed: 21357649
Invest New Drugs. 2012 Dec;30(6):2407-10
pubmed: 22231551
J Immunother. 2013 Jan;36(1):77-8
pubmed: 23211620
PLoS One. 2013;8(1):e53745
pubmed: 23341990
Clin Cancer Res. 2013 Apr 15;19(8):2232-9
pubmed: 23444228
Muscle Nerve. 2013 Sep;48(3):440-4
pubmed: 23447136
Pract Neurol. 2013 Aug;13(4):278-80
pubmed: 23487828
Exp Clin Endocrinol Diabetes. 2013 Nov;121(10):581-7
pubmed: 24122241
Neuro Oncol. 2014 Apr;16(4):589-93
pubmed: 24482447
J Clin Oncol. 2015 Nov 20;33(33):e122-4
pubmed: 24778401
Oncol Res Treat. 2014;37(6):351-3
pubmed: 24903767
J Neurol Sci. 2014 Sep 15;344(1-2):229-31
pubmed: 24980937
Mult Scler. 2015 Apr;21(5):670
pubmed: 25257614
J Immunother. 2015 Feb-Mar;38(2):77-9
pubmed: 25658617
J Oncol Pharm Pract. 2016 Jun;22(3):537-42
pubmed: 25712627
Muscle Nerve. 2015 Aug;52(2):307-8
pubmed: 25759003
Ocul Immunol Inflamm. 2016;24(2):140-6
pubmed: 25760920
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Lancet Oncol. 2015 May;16(5):522-30
pubmed: 25840693
Cancer Immunol Res. 2015 Jun;3(6):598-601
pubmed: 25922203
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
BMC Res Notes. 2015 Jul 26;8:316
pubmed: 26209970
Urologe A. 2015 Sep;54(9):1287-90
pubmed: 26337168
Urologe A. 2015 Oct;54(10):1443-5
pubmed: 26350358
Cancer Immunol Res. 2015 Dec;3(12):1299-302
pubmed: 26419960
Am J Med Sci. 2015 Dec;350(6):512-3
pubmed: 26488944
Jpn J Clin Oncol. 2016 Jan;46(1):86-8
pubmed: 26491202
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
Muscle Nerve. 2016 Sep;54(3):506-7
pubmed: 26802533
J Clin Oncol. 2016 Jul 1;34(19):2206-11
pubmed: 27001570
BMJ Case Rep. 2016 Mar 23;2016:
pubmed: 27009198
Nagoya J Med Sci. 2016 Feb;78(1):119-22
pubmed: 27019533
Muscle Nerve. 2016 Jun;54(1):157-61
pubmed: 27065302
Eur J Cancer. 2016 Jun;60:210-25
pubmed: 27084345
Muscle Nerve. 2016 Sep;54(3):507
pubmed: 27121245
Ann Oncol. 2016 Jul;27(7):1199-206
pubmed: 27122549
JAMA Neurol. 2016 Aug 1;73(8):928-33
pubmed: 27271951
Muscle Nerve. 2016 Sep;54(3):507-9
pubmed: 27287688
Ann Neurol. 2016 Aug;80(2):294-300
pubmed: 27351142
Jpn J Clin Oncol. 2016 Sep;46(9):875-8
pubmed: 27380808
Cancer Sci. 2016 Jul;107(7):1055-8
pubmed: 27420474
N Engl J Med. 2016 Jul 21;375(3):296-7
pubmed: 27468083
J Immunother Cancer. 2016 Aug 16;4:50
pubmed: 27532025
Eur J Surg Oncol. 2017 Mar;43(3):604-611
pubmed: 27769635
Melanoma Res. 2017 Apr;27(2):152-154
pubmed: 27776019
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
J Neurosurg Pediatr. 2017 Feb;19(2):249-253
pubmed: 27858578
Acta Derm Venereol. 2017 Mar 10;97(3):395-396
pubmed: 27868138
Curr Opin Oncol. 2017 Mar;29(2):136-144
pubmed: 28059853
Neuromuscul Disord. 2017 Mar;27(3):266-268
pubmed: 28109638
Eur J Cancer. 2017 Apr;75:24-32
pubmed: 28214654
Cancer Treat Rev. 2017 Mar;54:74-86
pubmed: 28231560
Tumour Biol. 2017 Mar;39(3):1010428317695013
pubmed: 28349816
Eur J Immunol. 2017 May;47(5):765-779
pubmed: 28393361
Ann Oncol. 2017 Feb 1;28(2):377-385
pubmed: 28426103
Oncologist. 2017 Jun;22(6):709-718
pubmed: 28495807
Oncologist. 2017 Jun;22(6):749-753
pubmed: 28559410
J Immunother. 2017 Sep;40(7):286-288
pubmed: 28604555
Case Rep Oncol. 2017 May 24;10(2):473-478
pubmed: 28626408
Medicine (Baltimore). 2017 Jul;96(27):e7350
pubmed: 28682883
J Immunother. 2018 Jan;41(1):35-38
pubmed: 29077601
Case Rep Med. 2017;2017:1093858
pubmed: 29312452
Front Immunol. 2018 Jan 30;9:108
pubmed: 29441072
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210